INNV Stock Forecast & Price Target

InnovAge Holding is positioned favorably because its F4Q26 results showed strong operating leverage, with EBITDA of $24.3M beating Street by 33% and revenue of $262.0M rising 18% y/y on 6.9% census growth, 10% revenue PMPM growth, and only 0.3% external cost PMPM growth. The outlook is further supported by FY27 guidance for EBITDA of $105M-$115M and revenue of $1,050M-$1,085M, alongside margin expansion to 10.3% at the midpoint, reflecting disciplined pricing, controlled medical costs, and continued investments in member experience, tech, and AI. Management also appears to have completed the turnaround, with census growing about 7%-10%, EBITDA recovering to roughly $90M in FY26, and a fragmented PACE market offering attractive consolidation opportunities through select M&A and operational optimization.

InnovAge Holding is exposed to meaningful regulatory and funding risk because about 55% of revenue comes from Medicaid, leaving it vulnerable to state budget pressure, Medicare/Medicaid rule changes, and potential sanctions on new member enrollment. Its profitability is also fragile because the business depends on maintaining margins in at-risk contracts, while the ongoing v28 risk-adjustment transition creates added uncertainty even if dementia coding may partly offset the impact for the roughly 40% of members with the disease. Although the PACE model shows strong evidence of lower hospitalizations, ED visits, and mortality, those benefits do not eliminate the risk that OBBB-related pressures or public health emergencies could strain volumes, reimbursement, and earnings quality.